PROSTATYPE GENOMICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0364 SEK | -3.70% |
|
-17.65% | -61.68% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Calendar
2024-05-22
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -61.68% | 3.43M | |
| -17.89% | 8.36B | |
| +40.16% | 3.6B | |
| -39.11% | 2.73B | |
| -8.06% | 2.47B | |
| -7.35% | 2.32B | |
| -11.62% | 1.77B | |
| -18.90% | 1.55B | |
| -40.19% | 1.22B | |
| +5.57% | 1.09B |
- Stock Market
- Equities
- PROGEN Stock
- News Prostatype Genomics AB
- Sweden's Prostatype Genomics Names New Chief Technology Officer
